Objective: To determine prognostic value of acoustic rhinometry in patients with perennial allergic rhinitis (PAR) treated with montelukast in fix combination with desloratidine and to assess effectiveness of this medication on health-related quality of life (HRQL). Study design: A randomized, double-blind, prospective and multicentric clinical study. Setting: Tertiary university hospitals. Methods: Patients 20 years of age and older with PAR were assessed over 3 months of treatment with fix combination of montelukast 10 mg plus desloratidine 5 mg once daily (n ¼ 40). Comparative acoustic rhinometric evaluation was used to compare nasal changes in before and after treatments. For evaluation of HRQL between before and after treatments at the first and third months, the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was used. Results: Nasal symptoms and findings including itching, sneezing, discharge, congestion and edema and color change of turbinates have been decreased after treatment. In acoustic rhinometry, minimum cross-sectional area (MCA) measurements and volume results were statistically higher than in before treatment (P , 0.001). Correlation was found that between the volume results and nasal discharged and/or congestion in right nasal passages. In left nasal passages, statistical relation was described between the MCA measurements and itching and/or change of turbinate color (P , 0.05). There was a larger decrease in the overall RQLQ score for the group using montelukast plus desloratidine compared with the pre-treatment scores (P , 0.001). The difference between scores at baseline versus the end of the first and third months for all domains was statically significant (P , 0.001). The treatment difference in change from first month to the end of the third month was statically significant, in favor of the third month, for eye, nose, and non-nose/eye symptoms, sleep, practical problems, emotions and activities that have been limited by nose or eye symptoms, and for overall score. Conclusions: Significant reductions in signs and symptoms of PAR with montelukast plus desloratadine treatment were accompanied by improved disease-specific QOL measures. Montelukast in combination with desloratidine provides improvements in acoustic rhinometric values including volume and MCA in patients with PAR. Acoustic rhinometry should be use in diagnostic and prognostic process in patients with PAR.
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HLA-B58 Does not Increase Allopurinol Hypersensitivity among Patients with Hematologic Malignancy
Jae-Woo Jung, Min-Hye Kim, Woo-Jung Song, Tae-Wan Kim, So-Hee Lee, Sae-Hoon Kim, Hye-Ryun Kang, Heung-Woo Park, Sun-Sin Kim, YoonSeok Chang, MD, PhD, Sang-Heon Cho, and Kyung-Up Min. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. Background: HLA-B58 is a very strong marker of allopurinol-induced severe cutaneous adverse reactions (SCARs), especially in population with high frequency of HLA-B58, such as Chinese, Thai, and Korean. Although allopurinol is frequently prescribed to patients receiving chemotherapy for the prevention of tumor lysis syndrome, the risk of allopurinol-related SCARs in patients with hematologic malignancies is not evaluated. This study was conducted to find out the incidence of allopurinol-induced hypersensitivity in patients with hematologic malignancy during chemotherapy according to HLA-B58 and clinical usefulness of HLA-B58 as a risk marker for the development of allopurinol-induced hypersensitivity. Methods: We retrospectively reviewed the medical records of patients with hematologic malignancy who ever took allopurinol and underwent serologic HLA typing for bone marrow transplantation from January 2000 to May 2010. Results: Among total 463 patients, 13 (2.8%) patients experienced allopurinol hypersensitivity reactions which were simple maculopapular rash and none of those were compatible with SCARs. The mean duration of allopurinol exposure in total patients was 26.46 days (1w2,173) and the mean duration until development of rash was 5.54 6 1.20 days. Fifty patients (10.8%) had HLA-B58. However, the incidence of allopurinol induced rash was not different according to HLA-B58 (4% (2/50) and 2.66% (11/413) in B58 (1) and B58 (-) patients, respectively). Frequency of B58 was slightly higher in patients with rash (15.4%) compared with tolerant patients (10.7%) but the difference was statistically insignificant (P . 0.05).
Conclusions:
The results of this study that HLA-B58 does not increase the risk of allopurinol induced SCARs as well as simple rash among patients with hematologic malignancy. Allopurinol can be used safely in most patients with hematologic malignancy during chemotherapy and HLA typing does not give additional advantage for clinical decision. Objective: Identify risk factors associated to mortality in pediatric patients with hemophagocytic lymphohistiocytosis. Methods: Retrospective cross-sectional study of medical records with discharge diagnosis of Hemophagocytic syndrome/Hemophagocytic lymphohistiocytosis (ICD-10; D76.1/D76.2) from Jan2004-May2011 in a pediatrictertiary-care-center. Descriptive and risk analysis were made on SPSS Statistics V17.0. Results: Thirty medical records were analyzed. Median-for-age: 2 years 8 months, (range: 2 months-to-15 years). Sex distribution: 14 girls (47%), 16 boys (53%). Median of symptoms duration: 1 month (range: 3 days-to-7 years). Reported symptoms and physical signs at hospital admission: fever n ¼ 28 (93%), asthenia/adynamia n ¼ 11 (37%), skin findings n ¼ 10 (33%), epistaxis n ¼ 5 (17%), gastrointestinal bleeding n ¼ 4 (13%), hepatomegaly n ¼ 27 (90%), splenomegaly n ¼ 21 (70%), lymphadenopathies n ¼ 14 (47%), paleness n ¼ 14 (47%), purpura n ¼ 5 (17%). Laboratory findings: anemia n ¼ 29 (97%), LDH elevation n ¼ 28 (93%), hypoalbuminemia n ¼ 27 (90%), thrombocytopenia n ¼ 26 (87%), hypertransaminasemia n ¼ 25 (83%), haemophagocytosis n ¼ 22 (73%), hypertrigliceridemia n ¼ 21 (70%), hypofibrinogenemia n ¼ 20 (67%), leucopenia n ¼ 19 (63%), hyperferritinemia n ¼ 15 (50%). In 18 patients (60%) active infection was evident at hospital admission: pneumonia n ¼ 9(50%), gastroenteritis n ¼ 2 (11%), meningitis n ¼ 1 (5%), others n ¼ 6 (33%). Epstein-Barr virus infection was diagnosed in 7 patients (23%). All patients were treated according to HLH-2004 guidelines. 
